GE Healthcare’s intravenous radiographic contrast agents iodixanol (Visipaque) and iohexol (Omnipaque) are currently in shortage due to a COVID-19-related shutdown in China.
In an April 2022 letter, GE Healthcare announced that its production facility for iodinated contrast media was temporarily shut down in Shanghai, China due to a recent COVID-19 outbreak in the city. The shutdown caused a supply issue that led to a rationing of its Omnipaque products.
The facility has since reopened and an increase in supply is expected through May and June. The Company anticipates a return to full stocking levels by July 2022.
- FDA drug shortages: Iodixanol (Visipaque) injection. US Food and Drug Administration. May 9, 2022. Accessed May 12, 2022. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iodixanol+%28Visipaque%29+Injection&st=c&tab=tabs-4&panels=0
- FDA drug shortages: Iohexol (Omnipaque) injection. US Food and Drug Administration. May 9, 2022. Accessed May 12, 2022. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol+%28Omnipaque%29+Injection&st=c&tab=tabs-4&panels=0
This article originally appeared on MPR